E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients 18 to 65 years old with HIV-associated visceral obesity, on a stable antiviral regimen for at least 6 weeks, with a viral load ≤1,000 copies/mL and CD4 count ≥200 cells/mm3, a body mass index (BMI) of ≥24 and ≤30 kg/m2, a waist-to-hip ratio of ≥0.95 in men or ≥0.90 in women, and a waist circumference of ≥90 cm in men or ≥85 cm in women. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC-1295 in patients with human immunodeficiency virus (HIV)-associated visceral obesity. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Able to provide written informed consent. 2. Age 18 to 65 years. 3. Documented HIV infection. 4. HIV-associated visceral obesity as judged by the Investigator and meeting the following criteria: - Waist-to-hip ratio associated with increased risk for cardiovascular disease (≥0.95 in men and ≥0.90 in women), - Waist circumference ≥90 cm in men and ≥85 cm in women, and - Body mass index (BMI) ≥24 or ≤30 kg/m2, calculated as described in Section 6.1.6. 5. Viral load ≤1,000 copies/mL. 6. CD4 count ≥200 cells/mm3. 7. On a stable antiviral regimen for at least 6 weeks prior to randomization. 8. Women with childbearing potential must provide a negative pregnancy test prior to randomization and must use an adequate, double-barrier contraceptive method. (Non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start). 9. Ability to understand study requirements and willingness to follow instructions, attend all required study visits, and undergo all planned procedures (including SC injections in the abdominal wall and drawing of blood samples). |
|
E.4 | Principal exclusion criteria |
1. Diabetes mellitus. 2. Fasting triglyceride level ≥11.3 mmol/L (1,000 mg/dL). 3. Unstable or untreated hypertension (>140/90 mmHg at screening). 4. Active malignancies. 5. BMI ≤24 or ≥30 kg/m2. 6. Hemoglobin <9 g/dL. 7. Use of GH or other GH secretagogues (except GHRH and GHRF, which may not have been used at all) within 3 months prior to randomization. 8. Previous use of GHRH or GHRF. 9. Use of (or anticipated need for) any of the following medications with 3 months prior to randomization: - systemic glucocorticoids, - megestrol acetate or other appetite stimulants, - general anorexigenic or weight-reducing agents, or - androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization. 10. History of carpal tunnel syndrome, unless resolved by surgical release. 11. Pregnant and/or breast-feeding women, or women within 3 months post-partum. 12. Hepatic transaminases >3 times the upper limit of normal (ULN). 13. Treatment with any investigational drug within 30 days prior to randomization. 14. Abnormal 12-lead ECG, which, in the opinion of the Investigator, is clinically significant. 15. Significant abnormality of the CT-scan (e.g., suspicion of tumor) as determined by the investigator. 16. Major illness within the past 4 weeks that is, in the opinion of the Investigator, clinically serious, unstable, and/or uncontrolled, or that would make the patient unsuitable for entry in the study. 17. Major surgery within 3 months prior to randomization and/or any surgery within 2 weeks of randomization, unless approved by the sponsor’s medical monitor or designee. 18. Donation of blood within 60 days of randomization. 19. Dependence on or abuse of alcohol, narcotic, opioid, or other addictive substances. 20. History of hypersensitivity to the study medication or to drugs with similar chemical structures. 21. History or suspicion of unreliability, poor cooperation or non-compliance with medical treatment. 22. Any concurrent disease or condition that, in the opinion of the Investigator, would make the patient unsuitable for participation in the study. 23. Previous enrollment in this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Endpoint
The primary efficacy endpoint is a percent change or absolute change in total IGF-1 levels from baseline comparing active and placebo-treated patients after 12 weeks of treatment.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |